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Abstract
Introduction. Even though EVLA is increasingly popular and together with other minimally-invasive techniques 
is rapidly replacing surgical stripping, surgical treatment is still widely used. Our study aimed to compare the 
clinical outcomes and the quality of life following either endovenous laser ablation (EVLA) or conventional surgery 
for varicose veins of the lower limbs.
Material and methods. This prospective non-randomised study included 299 patients, who were treated 
for symptomatic varicose veins of the lower limbs in two centres. In one, 159 patients underwent open surgery 
(the surgery group), while in the other, 140 patients received the EVLA (the EVLA group). The patients were 
invited to follow-up evaluations at six weeks, one year, and two years after the surgery.
Results. Disease-specific quality of life at six weeks was significantly better in the EVLA group (median AVVQ 
scores — 3.2 (2.1–8) vs. 9.2 (7.1–13.8), p < 0.001). Similarly, VCSS scores at six weeks were also better 
in the EVLA group (median VCSS scores — 1 (0–2) vs. 4 (3–6), p < 0.001). Patients in the EVLA group 
experienced less postoperative pain (p < 0.001), and therefore needed fewer supplementary analgesic drugs 
(p = 0.007). In addition, patients in the EVLA group managed to return to work and normal activities sooner 
than those in the surgery group (p < 0.001). No statistically significant differences were found between groups 
for clinical recurrence, overall satisfaction, rate of complications and secondary procedures.
Conclusions. Both treatment techniques yielded similar results in terms of efficacy, clinical recurrence rates 
and overall patient satisfaction. However, early postoperative results in the EVLA group were superior to those 
of patients in the surgery group.
Key words: varicose veins, endovenous laser ablation (EVLA), open surgical treatment, quality of 
life, Aberdeen Varicose Vein Questionnaire (AVVQ), Venous Clinical Severity Score
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Introduction
Varicose veins in the lower extremities is one of 
the most common diseases affecting 10−20% of the 
adult population [1]. The prevalence of the pathology 
increases with age — from 12% in the age group of 18− 
–24 years to 56% in individuals aged 55−64 years [2]. 
Having regard to the ageing of the human population, 
in several decades this disease is predicted to affect 
roughly half of the adult population [3]. Due to serious 
complications, and the development of trophic ulcers 
in particular, this pathology adversely affects the pa-
tients’ quality of life and places a heavy burden on the 
healthcare system [4].
The main objectives of the treatment for varicose 
veins include prevention of complications, alleviation of 
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symptoms, and improvement of the patients’ quality of 
life. The most common method of treatment for this 
condition is an open surgery proposed by W. Keller 110 
years ago [5]. During a surgical procedure, the saphe-
nofemoral junction is disconnected from the venous 
system via ligation in the case of the great saphenous 
vein disease or the saphenopopliteal junction is ligated 
in the case of the small saphenous vein damage. The 
ligation is usually followed by the great or the small 
saphenous vein removal (stripping).
The surgical intervention usually alleviates the 
symptoms and yields the desired results, yet some-
times the postoperative period is aggravated by the 
development of complications such as pain, bleeding, 
infection (inguinal or popliteal), thrombophlebitis, sa-
phenous nerve damage, or impaired lymph drainage. 
Furthermore, the procedure leaves postoperative scars 
and there is a risk of hyperpigmentation [6]. Moreover, 
recurrent varicose veins are known to be a common 
problem after surgery: the literature demonstrates 
a recurrence rate of 60% after 5 years of follow-up 
observation [7, 8]. The recurrence is mostly caused by 
neovascularisation, anatomic peculiarities (e.g. a double 
great saphenous vein), surgical technique errors, or an 
incomplete procedure [9].
The last decade has seen the emergence of minimal-
ly invasive methods of treatment for varicose veins, the 
endovenous laser ablation (EVLA) among them. EVLA 
is a percutaneous minimally invasive technique where 
a fibre laser is inserted under ultrasound guidance into 
the trunk of the affected vein. Within the lumen of 
the vein the energy generated by the laser produces 
temperature of up to 1000°C [10]. During EVLA, the 
walls of the vein are directly affected by the laser 
energy [11], heat [12], and steam bubbles [13], which 
results in venous wall microperforation due to the high 
temperature [14], eventually followed by shrinkage of 
the venous wall, complete subsequent scarification, 
and vein occlusion.
EVLA is a simpler and less complicated procedu- 
re [15]. The treatment requires only local rather than 
general or spinal anaesthesia. In addition, it can be done 
in a day surgery setting, which means that patients do 
not need to be hospitalised and they can sooner return 
to their normal life [16]. Moreover, laser ablation is 
associated with less postoperative pain, leaves no scars 
and may be applied in patients under anticoagulant 
therapy without the need to discontinue the treatment. 
Some authors claim that EVLA is superior to the 
conventional open surgical treatment because it is not 
only as radical as an open surgery but it is also charac-
terised by minimised tissue damage and thus a lower 
number of postoperative complications, a better index 
of the postoperative quality of life, a better cosmetic 
effect, and an earlier return to normal activity [17–19]. 
Although the procedure-related costs were found to be 
higher for EVLA than for conventional surgery [19, 20], 
EVLA has been identified as having the highest chance 
of being the most cost-effective method of treatment 
for varicose veins in the long term [21, 22].
Even though EVLA is increasingly popular and 
together with other minimally-invasive techniques is 
rapidly replacing surgical stripping, surgical treatment 
is still widely used.
Our study aimed to compare the clinical outcomes 
and the quality of life in patients with varicose veins 
of the lower limbs, who received endovenous laser 
ablation or open surgery.
Material and methods
The studied population
The prospective non-randomised study followed 
299 patients, who in 2012 through 2013 were treated 
for symptomatic varicose veins of the lower limbs in 
two centres. In one, 159 patients underwent open 
surgery (the surgery group), while in the other, 140 pa-
tients received an endovenous laser ablation (the EVLA 
group). The inclusion criteria were primary, sympto-
matic varicose veins with isolated saphenofemoral or 
saphenopopliteal junction incompetence and the great 
saphenous vein (GSV) or the small saphenous vein (SSV) 
reflux on duplex ultrasound imaging. The exclusion 
criteria were age under 18, CEAP clinical grades C1, 
C5 or C6, pregnancy or breastfeeding, III° obesity (BMI 
> 40 kg/m2), arterial insufficiency or incompetence of 
the deep venous system. For all patients, the surgery 
involved only one leg. Where the same patient received 
surgery of the second leg within the study period, only 
the first leg was included into the study. Thus the num-
ber of patients in this study corresponds to the number 
of legs operated on.
The clinical and demographic characteristics of the 
patients are presented in Table 1.
Data collection and analysis
The study protocol was approved by the Institu-
tional Review Board of our hospital. Patients who were 
found eligible for the study were asked to sign a written 
consent to participate in the study. Prior to the surgery, 
patients’ demographic data (sex, age at the time of the 
treatment, and BMI) were collected, the clinical grade 
according to the CEAP classification was determined, 
and the vein (the great saphenous vein [GSV] or the 
small saphenous vein [SSV]) to be surgically treated 
was recorded.
The severity of the symptoms was evaluated using 
the Venous Clinical Severity Score (VCSS). This is an 
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instrument based on the evaluation of nine main symp-
toms of the disease: pain, varicose veins, venous oede-
ma, skin pigmentation, inflammation, induration, and 
ulcers (duration, number, and size of active ulcers) [23]. 
The VCSS-based evaluation was conducted by a con-
sulting vascular surgeon. The total score ranges from 
0 (represents no significant venous disease) to 30 
(maximum).
Before the study, the patients were also asked to 
fill out the Aberdeen Varicose Veins Questionnaire 
(AVVQ). This questionnaire consists of 13 items al-
lowing for a detailed evaluation of the symptoms of 
chronic venous insufficiency. The AVVQ evaluation 
includes both symptoms (pain and itching) and clinical 
signs (oedema, hyperpigmentation, and ulceration). 
The questionnaire also includes questions related to 
the effect of the disease on the patient’s quality of life, 
which is highly important in the contemporary studies 
in the field of phlebology [24]. The total score of the 
questionnaire ranges from 0 (no effect on the quality 
of life) to 100 (a maximum effect).
The postoperative complications were grouped 
into: 1) minor, which do not require hospitalisation; 
and 2) major, which cause long-term adverse effects 
or death, and require hospitalisation and treatment.
Postprocedural pain scores and the intake of anal-
gesics were evaluated during the first seven days after 
the procedure at the end of the day. Pain scores were 
taken by the patient with the help of a 10-cm visual 
analogue scale (0 — no pain, 10 — the greatest pain). 
In addition, the time needed to return to normal activity 
and work was also registered.
Interventions
All patients were marked before the surgery or 
EVLA using guidance by duplex ultrasonography. 
An open surgery was performed under general or 
spinal anaesthesia. Depending on whether the trunk of 
the GSV or the SSV was affected, usually either the sa-
phenofemoral or saphenopopliteal junction was ligated 
and the respective trunk was stripped.
EVLA was performed under perivenous tumescent 
anaesthesia with 0.05% lidocaine. The mean volume of 
applied tumescence fluid was 425 mL (SD 105; range 
250−575) when cooled solution was used, and 225 mL 
(SD 75; range 200−425) when warm solution was used. 
The procedure started with a percutaneous insertion 
of a 19-G needle into the affected venous trunk under 
ultrasound guidance. Subsequently, a guidewire was 
passed through the needle to the site of the saphe-
nofemoral or saphenopopliteal junction. Then the 
needle was removed, and a 5-Fr catheter was inserted 
over the guidewire. Finally, the guidewire was removed 
and an optical fibre was inserted approximately 1−2 cm 
distal from the saphenofemoral or saphenopopliteal 
junction. The laser energy was obtained by applying 
Table 1. Clinical and demographic characteristics of patients in the study group
Conventional surgery (N = 159) EVLA (N = 140) p
Age (years)
Mean 51.1 (SD 12.6) 50.2 (SD 13.9) 0.106
Range 21−73 19−80
Sex, males / females 51 (32.1%) / 108 (67.9%) 32 (22.9%) / 108 (77.1%) 0.076
BMI [kg/m2]
Mean 28 (SD 5.3) 26.7 (SD 5) 0.068
Range 16.4−39.8 16.3−38.1
Obesity (BMI > 30 kg/m2) 58 (36.5%) 35 (25%) 0.032
Operated vein 
Great saphenous vein 131 (82.4%) 106 (75.7%) 0.155
Small saphenous vein 21 (13.2%) 25 (17.9%) 0.267
Both 7 (4.4%) 9 (6.4%) 0.435
CEAP clinical grade
C2 20 (11.8%) 76 (51.7%) < 0.001
C3 100 (58.8%) 43 (29.3%) < 0.001
C4 39 (22.9%) 21 (14.3%) 0.040
Baseline VCSS (median) 5 (IQR 3−7) 5 (IQR 2.5−6) 0.728
Baseline AVVQ (median) 16.1 (IQR 9.5−21) 15.6 (IQR 8.6−19.5) 0.270
IQR — interquartile range; SD — standard deviation
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a 1470-nm diode laser generator probe with a radial-tip 
fibre (Ceralas E, Biolitec, Jema, Germany). A 400-mi-
cron fibre and the power of 6 W was used for ablation 
of small diameter veins (6−7 mm), while a 600-micron 
fibre and the power of 10 W was used in cases of bigger 
diameter veins. Our protocol totally delivered 7 J × 
diameter of vein (mm) of laser energy per cm of treated 
vein. During the infrapopliteal ablation procedure, the 
amount of energy was modified by the time of exposure 
according to the diameter of the vein. EVLA treatment 
data are given in Table 2.
In both patient groups, the varicosities and incom-
petent perforators in the thigh and/or the calf were 
removed by performing mini-phlebectomies via stab 
incisions over varicose tributaries, which were avulsed 
using a vein hook or a Kocherised mosquito clamp.
The mean duration of surgery was 62.5 (SD 14.1; range 
25−90) minutes, while EVLA lasted for 55.6 (SD 12.8; 
range 20−75) minutes (p = 0.148).
Postoperative care
The postoperative management was the same for 
both groups. After the procedure, a non-stretch com-
pression bandage was applied on patient’s leg. After 48 
hours, the patient removed the bandage and continued 
using an elastic class II compression stocking during 
the day only for at least one week after the operation. 
On the day of surgery 2500 to 3500 IU of bemiparin 
was administered subcutaneously for the prevention 
of deep vein thrombosis. All patients were advised to 
mobilise immediately after the treatment. In addition, 
the patients were administered analgesics for pain 
management postoperatively.
Follow-up
The patients were invited to follow-up evaluations 
by a vascular surgeon at six weeks, one year, and two 
years after the surgery. The evaluation included patient 
examination, clinical examination, assessment of the 
VCSS, the overall satisfaction with the operation, and 
disease recurrence. Patient’s satisfaction was assessed 
by asking whether the patient would agree to undergo 
same intervention again if necessary, or recommend 
it to a friend. Clinical recurrence was defined as new 
varicose tributaries at least 3 mm in diameter arising 
after treatment.
During the follow-up evaluations, the patients filled 
out the AVVQ questionnaire again. Some of the patients 
either could not or refused to arrive for follow-up 
evaluation and thus they were interviewed in great 
detail via telephone. A complete follow-up was available 
for all the patients at six weeks. However, at one and 
two years after the treatment, 92 patients (38 and 54, 
respectively) were lost to follow-up and thus a total 
of 207 (111 patients (69.8%) in surgery group and 96 
patients (68.6%) in EVLA group) were followed until 
the end of the study.
Statistical analysis
Statistical analysis was performed using SPSS 22.0 
software package (IBM, Armonk, New York, USA). 
Normality of data was checked by the Kolmogor-
ov-Smirnov test. Normally distributed data are pre-
sented as mean together with standard deviation (SD) 
and compared with paired and unpaired Student’s 
t-tests. Non-parametric data are presented as median 
together with interquartile range (IQR) and compared 
using the Mann-Whitney U test for unrelated samples 
and the Wilcoxon signed ranks test for paired data. 
Categorical variables were compared using chi-square 
(c2) and Fisher’s exact test.
We considered p values of less than 0.05 statistically 
significant.
Results
Disease-specific quality of life (Aberdeen  
Varicose Vein Questionnaire)
Compared with the baseline scores, at one and two 
years after the treatment the improvement in the AVVQ 
scores was statistically significant in both patient groups 
(p < 0.001). At baseline, the AVVQ scores did not 
show a statistically significant difference between the 
surgery and the EVLA groups. However, six weeks after 
the treatment, statistically significantly lower AVVQ 
scores were observed in the EVLA group (p < 0.001). 
At one year after the treatment the results were re-
versed: statistically significantly lower AVVQ scores 
and better disease-specific quality of life (QoL) were 
observed in the surgery group (p < 0.001). At two years 
after the surgery, the results remained the same as one 
year before, i.e. statistically significantly lower AVVQ 
scores were found in the surgery group (p = 0.001). 
Table 2. EVLA treatment data for great saphenous vein (GSV) 
and small saphenous vein (SSV) ablation. The data are pre-
sented as mean (range)
GSV (N = 106) SSV (N = 25)
Length of ablated  
vein [cm] 
36 (3−90) 21 (3−40)
Diameter of ablated  
vein [mm]
9.1 (5−28) 7.1 (5−23)
Total energy  
delivery [J]
2569  
(420−5040)
1512 
(350−2898)
Energy density [J/cm] 74.5 
(38.2−132.5)
75  
(35−117.4)
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Table 3 shows the AVVQ scores over different periods 
of treatment and with different CEAP clinical grades.
Venous Clinical Severity Score
Compared with the baseline scores, at one and 
two years after the treatment the VCSS scores sta-
tistically significantly improved in both patient groups 
(p < 0.001). At baseline, there was no difference in the 
VCSS scores between the analysed groups. Six weeks 
after the treatment, the VCSS score in the surgery 
group was statistically significantly (p < 0.001) higher. 
However, at one and two years after the intervention 
the VCSS scores converged and the difference between 
the groups was no longer statistically significant. Table 4 
presents the VCSS scores during different periods of 
treatment and with different CEAP clinical grades.
Complications
In total, 20 (14.3%) patients in the EVLA group 
and 35 (22%) patients in the surgery group devel-
oped minor complications during the first six weeks 
(p = 0.085). Haematomas were more common in the 
surgery group, while discoloration occurred more 
frequently in patients of the EVLA group. The rates 
of minor complications which occurred in the first six 
weeks after both methods of treatment are presented 
in Table 5. During the study period, neither group of 
patients experienced deep vein thrombosis, skin ne-
crosis or other major complications. 
Early postoperative pain and analgesia use
Better results of early disease-specific QoL in EVLA 
group were also reflected by less reported postoperative 
pain compared with patients in the surgery group (Fig. 1). 
As a result of this, a higher proportion of patients in the 
surgery group required supplementary analgesic drugs 
during the first week after the procedure (p = 0.007).
Return to work and normal activities
The median duration of time needed to return to 
normal activities after the treatment was 14 days (range 
5−25) in the surgery group and four days (range 1−14) 
in the EVLA group (p < 0.001). Employed patients in 
the EVLA group also managed to return to work soon-
er than patients in the surgery group (14 days (range 
5−30) vs. 5 days (range 1−30); p < 0.001).
Clinical recurrence
The analysis of clinical recurrence did not yield 
any statistically significant results. After one year the 
Table 3. AVVQ results in patients with different clinical grades of CEAP classification at different time intervals after the treat-
ment. Also AVVQ results in patients with GSV or SSV procedure. The data are presented as median (IQR)
6 weeks 1 year 2 years
AVVQ p AVVQ p AVVQ p
C2
Surgery 9.2 (7.4−13) < 0.001 1.3 (0.6−5.6) SN 1.3 (0−7.8) SN
EVLA 2.6 (1.3−3.8) 1.3 (0−4.3) 2.1 (0−6.9)
C3
Surgery 8.4 (4.3−11.9) < 0.001 0 (0−2.9) < 0.001 0.6 (0−3.6) < 0.001
EVLA 2.6 (2.2−5.3) 5.2 (1.3−7.2) 3.3 (1.1−7.5)
C4
Surgery 13 (8.9−20) 0.007 1.3 (0−2.6) 0.018 1.3 (0−6.6) 0.024
EVLA 8.7 (6.8−19) 6.2 (3.8−7.5) 6 (0−11.8)
GSV
Surgery 9.2 (7.1−12.1) < 0.001 0 (0−2.25) 0.027 1.7 (0−4.3) < 0.001
EVLA 2.6 (2.1−6.9) 1.9 (0−6.6) 4.8 (0.2−8.7)
SSV
Surgery 9.6 (5.1−18.3) 0.012 0 (0−2.6) 0.045 0 (0−0.6) 0.002
EVLA 6 (1.3−12.2) 2.6 (0−5.5) 3.1 (1.4−11.5)
All patients
Surgery 9.2 (7.1−13.8) < 0.001 0 (0−2.25) < 0.001 1 (0−4.3) 0.001
EVLA 3.2 (2.1−8) 2.3 (0−6.6) 2.4 (0.2−6.8)
SN — statistically not significant; GSV — great saphenous vein; SSV — small saphenous vein
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condition recurred in 5.2% (n=5) of the patients in 
the EVLA group and in 4.5% (n=5) of the patients in 
the surgery group (p = 0.810). The recurrence rates at 
two years after the intervention were 14.6% (n=14) 
in the EVLA group and 13.5% (n=15) in the surgery 
group (p = 0.826).
Overall satisfaction
At two years after the intervention 88.5% (n=85) 
of the patients in the EVLA group and 94.6% (n=105) 
of the patients in the surgery group claimed that they 
would choose the same technique if they needed such 
treatment again or would recommend this technique 
to others (p = 0.114).
Secondary procedures
At one year after the treatment six patients in the 
EVLA group required secondary interventions: two 
patients needed surgical treatment (phlebectomy) and 
four patients chose aesthetic procedures (sclerotherapy 
of reticular veins and telangiectasias). Meanwhile, in 
the surgery group the need for secondary procedures 
Table 5. The rates of minor complications which occurred in the first six weeks after EVLA and conventional surgery
Complication EVLA (N = 140) 
No. (%)
Conventional surgery (N = 159) 
No. (%)
p
Symptomatic phlebitis 5 (3.6%) 7 (4.4%) 0.711
Bruising 2 (1.4%) 3 (1.9%) 0.757
Hematoma 2 (1.4%) 10 (6.3%) 0.032
Discoloration 6 (4.3%) 1 (0.6%) 0.037
Infection 1 (0.7%) 4 (2.5%) 0.226
Sensory disturbance (e.g. paraesthesias) 4 (2.9%) 10 (6.3%) 0.162
Table 4. VCSS results in patients with different clinical grades of CEAP classification at different time intervals after the treat-
ment. Also VCSS results in patients with GSV or SSV procedure. The data are presented as median (IQR)
6 weeks 1 year 2 years
VCSS p VCSS p VCSS p
C2
Surgery 4.5 (4−5) < 0.001 0 (0−2) SN 2 (0.75−4) SN
EVLA 0 (0−1) 0 (0−2) 2 (0−2)
C3
Surgery 4 (2.5−6) < 0.001 0 (1−2) SN 0 (1−2.5) SN
EVLA 0 (0−1) 0 (1−2) 0 (1−2.5)
C4
Surgery 5.5 (3.8−8.5) 0.038 1 (1−2) 0.014 1 (0−4.5) SN
EVLA 2 (1.5−5) 5 (0−6.5) 2 (0−5)
GSV
Surgery 4 (3−6) < 0.001 1 (0−2) SN 1 (0−3) SN
EVLA 0.5 (0−1.75) 1 (0−2) 2 (0−2.75)
SSV
Surgery 5 (4−7.5) < 0.001 0.5 (0−2) SN 0.5 (0−1.3) SN
EVLA 2 (0−3.5) 0.5 (0−2) 1 (0.3−6.3)
All patients
Surgery 4 (3−6) < 0.001 1 (0−2) SN 1 (0−3) SN
EVLA 1 (0−2) 1 (0−2) 1 (0−2)
SN — statistically not significant; GSV — great saphenous vein; SSV — small saphenous vein
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arose in four patients: two patients needed surgical 
treatment and two chose aesthetic procedures. A year 
later, nine patients in the EVLA group received addi-
tional procedures: two EVLA, four aesthetic proce-
dures, and three phlebectomies. At two years after the 
treatment, six patients in the surgery group required 
additional interventions: three phlebectomies and three 
aesthetic treatments. In total, at two years after the in-
itial treatment, additional interventions were chosen by 
15 patients (15.6%) in the EVLA group and 10 patients 
(9%) in the surgery group (p = 0.144).
Discussion
Results obtained in our study confirm that EVLA is 
not only as effective as surgical stripping but also pro-
vides significantly better quality of life during the early 
post-treatment period and earlier return to work and 
normal activities. 
In our study, 6 weeks after the treatment, statis-
tically significantly lower AVVQ scores in all CEAP 
clinical grades were observed in the EVLA group. This 
shows that during the short postoperative period dis-
ease-specific quality of life was better after EVLA. At 
one and two years after the treatment better AVVQ 
scores were found in the surgery group. In a randomised 
controlled study [21] conducted in 2015, which included 
294 patients in the surgery group and 212 patients in 
the EVLA group, no statistically significant differences 
in the AVVQ scores between the EVLA and the sur-
gery groups were found six weeks or six months after 
the treatment. A study by Mekako et al. [18] yielded 
similar results to those obtained in our study, i.e. 
a better disease-specific QoL in the EVLA group 6 and 
12 weeks after treatment. So far there have been few 
studies analysing the AVVQ in different CEAP clinical 
grades. The results of our study showed that in clinical 
class C2, at one and two years after the initial treatment 
the AVVQ scores did not differ statistically significantly 
between the surgery and the EVLA groups. Meanwhile, 
at one and two years after the intervention in classes 
C3 and C4 statistically significantly better results were 
observed in the surgery group.
Most of the studies described in the literature in-
dicate that after the treatment the clinical symptoms 
decrease equally statistically significantly and no differ-
ence in the VCSS between the surgery and the EVLA 
groups is found [20, 21, 25–29]. In this study, six weeks 
after the treatment statistically significantly lower VCSS 
scores in all CEAP clinical grades were observed in the 
EVLA group. At one and two years after the interven-
tion the treatment results in the groups converged and 
the difference was no longer statistically significant. The 
only exception was the C4 clinical group, where at one 
year after the treatment the VCSS scores were better 
in the surgery group.
In literature clinical recurrence at two years after 
the initial intervention ranges between 7% and 37% 
in the surgery group, and between 7% and 26% in 
the EVLA group [28, 30]. In our study, at two years 
after the initial treatment the clinical recurrence rate 
in the EVLA group and the surgery group was 14.6% 
and 13.5%, respectively, yet the difference was not 
statistically significant. Most of the studies also found 
no statistically significant difference between the groups 
at one or two years after the treatment [28, 30–32]. 
Carradice et al. [33] found the clinical recurrence rate 
at one year to be lower after EVLA than after surgery 
(p < 0.001). Theivacumar et al. [30] did not find any 
statistically significant difference in clinical recurrence 
between the groups at two years after the treatment, 
although neovascularization was detected in 18% of 
the surgery group patients compared to only 1% of 
the EVLA group patients (p < 0.001). The results of 
a randomised controlled trial [29] conducted in 2013 
showed no difference in recurrence rates at five years 
after the initial treatment.
Concerning the patients’ overall satisfaction with 
the treatment, the available studies do not present any 
statistically significant results [25, 30, 34, 35]. Although 
in our study a slightly higher percentage of patients who 
received open surgery claimed that they would choose 
the same technique again or would recommend it to 
their relatives or friends, the difference between the 
surgery and the EVLA groups was not statistically sig-
nificant. Furthermore, we can assume that the patient’s 
overall satisfaction was also influenced by the fact that 
in Lithuania EVLA is not yet fully compensated by the 
National Health Insurance Fund, therefore patients 
likely had higher expectations for this procedure.
Figure 1. Mean postoperative pain score (using a visual ana-
logue scale) during the first seven days after EVLA and con-
ventional surgery. The difference between the curves was 
statistically significant (p < 0.001)
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In this study, several potential limitations merit 
consideration. First, our study was non-randomised; 
as a result there were some differences between 
study groups at baseline (number of obese patients, 
proportions of CEAP clinical grades). Moreover, EVLA 
and open conventional surgeries were performed in 
different centres, also, open surgeries were done by 
several different vascular surgeons. Furthermore, we 
included patients with both SSV and GSV disease in 
our analysis. 
Conclusions
Both techniques — EVLA and surgery — yielded 
similar results in terms of efficacy, clinical recurrence 
rates and overall patient satisfaction. Although in the 
present study we did not find EVLA to be superi-
or to surgical stripping in the long term, during the 
short postoperative period, results in the EVLA group 
were significantly better than those of the surgery 
group. Therefore, we assume that EVLA should be 
recommended over surgical stripping, especially for 
patients who find good quality of life during the early 
post-treatment period and early return to work and 
normal activity important.
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